XML 46 R13.htm IDEA: XBRL DOCUMENT
v3.20.1

Stockholder's Equity | 3 Months Ended
--- | ---
Mar. 31, 2020
Equity [Abstract] |
Stockholder's Equity |
8. | Stockholders’ Equity
Authorized, Issued, and Outstanding Common Stock The Company’s authorized common stock has a par value of $0.001 per share and consists of 250,000,000 shares as of March 31, 2020, and December 31, 2019; 97,876,042 and 97,413,721 shares were issued and outstanding at March 31, 2020, and December 31, 2019, respectively. The following table summarizes common stock share activity for the three months ended March 31, 2020 and 2019 (dollars in thousands):
|  | Three Months Ended March 31, 2020 |
|  | Shares of Common Stock |  |  | Common Stock |  |  | Additional Paid-in Capital |  |  | Accumulated Deficit |  |  | Total Stockholders’ Equity |
Balance, December 31, 2019 |  |  | 97,413,721 |  |  | $ | 97 |  |  | $ | 284,226 |  |  | $ | (271,428 | ) |  | $ | 12,895 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (7,002 | ) |  |  | (7,002 | )
Stock-based compensation expense |  |  | — |  |  |  | — |  |  |  | 410 |  |  |  | — |  |  |  | 410 |
Common stock issued through employee stock purchase plan |  |  | 22,143 |  |  |  | — |  |  |  | 18 |  |  |  | — |  |  |  | 18 |
Common stock issued, net of expenses |  |  | 285,276 |  |  |  | 1 |  |  |  | 206 |  |  |  | — |  |  |  | 207 |
Common stock issued for vested restricted stock units |  |  | 154,902 |  |  |  | — |  |  |  | (73 | ) |  |  | — |  |  |  | (73 | )
Balance, March 31, 2020 |  |  | 97,876,042 |  |  | $ | 98 |  |  | $ | 284,787 |  |  | $ | (278,430 | ) |  | $ | 6,455 |
|  | Three Months Ended March 31, 2019 |
|  | Shares of Common Stock |  |  | Common Stock |  |  | Additional Paid-in Capital |  |  | Accumulated Deficit |  |  | Total Stockholders’ Equity |
Balance, December 31, 2018 |  |  | 47,971,989 |  |  | $ | 48 |  |  | $ | 248,895 |  |  | $ | (217,718 | ) |  | $ | 31,225 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (22,908 | ) |  |  | (22,908 | )
Stock-based compensation expense |  |  | — |  |  |  | — |  |  |  | 492 |  |  |  | — |  |  |  | 492 |
Common stock issued through employee stock purchase plan |  |  | 19,259 |  |  |  | — |  |  |  | 20 |  |  |  | — |  |  |  | 20 |
Common stock issued, net of expenses |  |  | 2,226,569 |  |  |  | 2 |  |  |  | 2,507 |  |  |  | — |  |  |  | 2,509 |
Common stock issued for vested restricted stock units |  |  | 14,612 |  |  |  | — |  |  |  | (8 | ) |  |  | — |  |  |  | (8 | )
Balance, March 31, 2019 |  |  | 50,232,429 |  |  | $ | 50 |  |  | $ | 251,906 |  |  | $ | (240,626 | ) |  | $ | 11,330 |
Shares Reserved for Future Issuance The Company had reserved shares of common stock for future issuance as follows:
| March 31, 2020 |  |  | December 31, 2019 |
Outstanding stock options |  | 7,684,762 |  |  |  | 5,261,860 |
Outstanding restricted stock units |  | 862,514 |  |  |  | 966,394 |
Warrants to purchase common stock associated with June 2016 Public Offering |  | 4,218,750 |  |  |  | 4,218,750 |
Warrants to purchase common stock associated with March 2018 Public Offering – Series 2 |  | 7,988,175 |  |  |  | 7,988,175 |
Warrants to purchase common stock associated with December 2019 Public Offering |  | 44,722,222 |  |  |  | 44,722,222 |
Option to purchase common stock associated with December 2019 Public Offering |  | — |  |  |  | 5,833,333 |
Warrants to purchase common stock associated with Solar loan agreement |  | 122,435 |  |  |  | 122,435 |
For possible future issuance for the conversion of the 6% senior convertible notes |  | 11,382,000 |  |  |  | 11,382,000 |
For possible future issuance under 2014 Equity Incentive Plan (Note 9) |  | 1,900,861 |  |  |  | 554,774 |
For possible future issuance under Employee Stock Purchase Plan |  | 81,499 |  |  |  | 74,231 |
For possible future issuance under 2015 Inducement Award Plan (Note 9) |  | 315,500 |  |  |  | 315,500 |
Total common shares reserved for future issuance |  | 79,278,718 |  |  |  | 81,439,674 |
Convertible Debt and Derivative Liability In connection with the Company’s issuance of its Notes, the Company bifurcated the embedded conversion option, inclusive of the interest make-whole provision and make-whole fundamental change provision, and recorded the embedded conversion option as a long-term derivative liability in the Company’s balance sheet in accordance with ASC 815, Derivatives and Hedging. The convertible debt and derivative liability associated with the Notes are presented in total on the accompanying unaudited condensed consolidated balance sheets as the convertible debt and derivative liability. The derivative liability will be remeasured at each reporting period using the binomial lattice model with changes in fair value recorded in the statements of operations in other (income) expense. For the three months ended March 31, 2020 and 2019, the Company recorded a gain of $0.7 million and a loss of $3.4 million due to the change in fair value of the derivative liability. Warrants Associated with June 2016, March 2018, and December 2019 Public Offerings The outstanding warrants associated with the June 2016, March 2018, and December 2019 public offerings contain a provision where the warrant holder has the option to receive cash, equal to the Black-Scholes fair value of the remaining unexercised portion of the warrant, as cash settlement in the event that there is a fundamental transaction (contractually defined to include various merger, acquisition or stock transfer activities). Due to this provision, ASC 480, Distinguishing Liabilities from Equity, requires that these warrants be classified as liabilities. The fair values of these warrants have been determined using the Black-Scholes valuation model, and the changes in the fair value are recorded in the accompanying unaudited condensed consolidated statements of operations. During the three months ended March 31, 2020 and 2019, the Company recorded a gain of $4.8 million and a loss of $6.5 million, respectively, due to the change in fair value of the warrant liabilities. As of March 31, 2020, the fair value of the warrant liabilities was $13.6 million. Warrant Associated with Solar Loan Agreement On the closing date of the Company’s previous loan agreement with Solar, pursuant to the loan agreement the Company issued to Solar the warrant to purchase an aggregate of up to 122,435 shares of the Company’s common stock at an exercise price of $3.6754 per share. The warrant will expire five years from the date of the grant. The warrant was classified as equity and recorded at its relative fair value at issuance in the stockholders’ equity section of the balance sheet.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration